Schlieren (Switzerland), 23rd March 2023 – hemotune AG, the Schlieren-based MedTech company known for its magnetic blood purification platform announces a joint feasibility project with the global pharmaceutical company AstraZeneca.
Clinical Development Press Release
hemotune AG initiates joint feasibility project on the HemoSystem with AstraZeneca
Schlieren (Switzerland), 23rd March 2023 – hemotune AG, the Schlieren-based MedTech company known for [...]
Continue reading
Clinical Development Innovation Press Release
At the forefront of research into prevention of scar tissue formation after a heart attack
Resistell’s first patients recruited for international clinical study [...]
Continue reading
Clinical Development Innovation Press Release
Resistell’s first patients recruited for international clinical study in Switzerland, Spain and Austria
Resistell’s first patients recruited for international clinical study [...]
Continue reading
Innovation Investment Press Release
Reaching for the stars – ASPIVIX receives 510(k) clearance of Carevix™, Their Novel ATRAUMATIC Cervical Stabilizer from the U.S. FDA
HEMEX is proud to announce that our portfolio company ASPIVIX has received 510(k) clearance of [...]
Continue reading
Diversity Hemex Team Innovation
Empowering our people, transforming our world in 2023
New Year's resolutions can be a powerful way to make positive changes in life and [...]
Continue readingClinical Development, Innovation, Press Release
At the forefront of research into prevention of scar tissue formation after a heart attack
Resistell’s first patients recruited for international clinical study
Clinical Development, Innovation, Press Release
Resistell’s first patients recruited for international clinical study in Switzerland, Spain and Austria
Resistell’s first patients recruited for international clinical study
Innovation, Investment, Press Release
Reaching for the stars – ASPIVIX receives 510(k) clearance of Carevix™, Their Novel ATRAUMATIC Cervical Stabilizer from the U.S. FDA
HEMEX is proud to announce that our portfolio company ASPIVIX has received 510(k) clearance of Carevix™ from the U.S. Food and Drug Administration (FDA). ASPIVIX’s novel Cervical Stabilizer will allow millions of women across the USA access to significantly less painful treatments and IUD insertions.
New Year’s resolutions can be a powerful way to make positive changes in life and achieve goals.
Innovation, Investment, Press Release
Moving forward fast – ASPIVIX is finishing the 2022 with a new investment and a generous grant.
We are thrilled to share that HEMEX is part of the investment consortium financing the series B1 of hemotune AG. At HEMEX, we look forward to support hemotune on the journey to making the HemoSystem available to patients globally.
We are thrilled to share that HEMEX is part of the investment consortium financing the series B1 of hemotune AG. At HEMEX, we look forward to support hemotune on the journey to making the HemoSystem available to patients globally.
Increasing patients’ safety and care in research is vital when preparing and conducting your study. From a HEMEX perspective, we are tackling in this article four important points you should consider during the process.
We are thrilled to share that HEMEX is part of the investment consortium financing the series B1 of hemotune AG. At HEMEX, we look forward to support hemotune on the journey to making the HemoSystem available to patients globally.
From market research to funding, today, we will dismantle the top 5 reasons for startup failure. At HEMEX, we have seen many cases in our years of experience in this field. For this reason, we hope to give you some hints to look out for while navigating the ever-changing startup ecosystem.